Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson medTech Segment Total — Worldwide sales ($M) ($M)
Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule
Latest, Q3 2026
8,642
Period ended Sep 30, 2026
Change on a year earlier
+2.5%
8,430 in Q3 2025
History
43 quarters
Since Q1 2016
Sources
24
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | MedTech Segment Total — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 8,642 | +2.5% | Form 10-Q (filed 2026-10-21) ↗ |
| Q2 2026 | Jun 28, 2026 | 8,926 | +4.5% | Form 10-Q (filed 2026-07-23) ↗ |
| Q1 2026 | Mar 29, 2026 | 8,636 | +7.7% | Form 10-Q (filed 2026-04-22) ↗ |
| Q4 2025 | Dec 28, 2025 | 8,801 | +7.5% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2025 | Sep 28, 2025 | 8,430 | +6.8% | Form 10-Q (filed 2026-10-21) ↗ |
| Q2 2025 | Jun 29, 2025 | 8,541 | +7.3% | Form 10-Q (filed 2026-07-23) ↗ |
| Q1 2025 | Mar 30, 2025 | 8,020 | +2.5% | Form 10-Q (filed 2026-04-22) ↗ |
| Q4 2024 | Dec 29, 2024 | 8,188 | +6.7% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2024 | Sep 29, 2024 | 7,891 | +5.8% | Form 10-Q (filed 2025-10-22) ↗ |
| Q2 2024 | Jun 30, 2024 | 7,957 | +2.2% | Form 10-Q (filed 2025-07-24) ↗ |
| Q1 2024 | Mar 31, 2024 | 7,821 | +4.5% | Form 10-Q (filed 2025-04-23) ↗ |
| Q4 2023 | Dec 31, 2023 | 7,673 | +13.2% | Form 10-K (filed 2024-02-16) ↗ |
| Q3 2023 | Oct 1, 2023 | 7,458 | +10.0% | Form 10-Q (filed 2024-10-23) ↗ |
| Q2 2023 | Jul 2, 2023 | 7,788 | +12.9% | Form 10-Q (filed 2024-07-25) ↗ |
| Q1 2023 | Apr 2, 2023 | 7,481 | +7.3% | Form 10-Q (filed 2024-05-01) ↗ |
| Q4 2022 | Jan 1, 2023 | 6,776 | -1.2% | Form 10-K (filed 2024-02-16) ↗ |
| Q3 2022 | Oct 2, 2022 | 6,782 | +2.1% | Form 10-K (filed 2024-02-16) ↗ |
| Q2 2022 | Jul 3, 2022 | 6,898 | -1.1% | Form 10-K (filed 2024-02-16) ↗ |
| Q1 2022 | Apr 3, 2022 | 6,971 | +6.0% | Form 10-K (filed 2024-02-16) ↗ |
| Q4 2021 | Jan 2, 2022 | 6,859 | +4.1% | Form 10-K (filed 2024-02-16) ↗ |
| Q3 2021 | Oct 3, 2021 | 6,644 | +8.0% | Form 10-Q (filed 2022-10-27) ↗ |
| Q2 2021 | Jul 4, 2021 | 6,978 | +62.7% | Form 10-Q (filed 2022-07-29) ↗ |
| Q1 2021 | Apr 4, 2021 | 6,579 | +10.9% | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2020 | Jan 3, 2021 | 6,589 | -0.6% | Form 10-K (filed 2023-02-16) ↗ |
| Q3 2020 | Sep 27, 2020 | 6,150 | -3.7% | Form 10-Q (filed 2021-10-29) ↗ |
| Q2 2020 | Jun 28, 2020 | 4,288 | -33.9% | Form 10-Q (filed 2021-07-29) ↗ |
| Q1 2020 | Mar 29, 2020 | 5,932 | -8.2% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2019 | Dec 29, 2019 | 6,632 | -0.5% | Form 10-K (filed 2020-02-18) ↗ |
| Q3 2019 | Sep 29, 2019 | 6,383 | -3.1% | Form 10-Q (filed 2020-10-23) ↗ |
| Q2 2019 | Jun 30, 2019 | 6,489 | -6.9% | Form 10-Q (filed 2020-07-24) ↗ |
| Q1 2019 | Mar 31, 2019 | 6,459 | -4.6% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2018 | Dec 30, 2018 | 6,668 | -4.4% | Form 10-K (filed 2019-02-20) ↗ |
| Q3 2018 | Sep 30, 2018 | 6,587 | -0.2% | Form 10-K (filed 2019-02-20) ↗ |
| Q2 2018 | Jul 1, 2018 | 6,972 | +3.7% | Form 10-K (filed 2019-02-20) ↗ |
| Q1 2018 | Apr 1, 2018 | 6,767 | +7.5% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2017 | Dec 31, 2017 | 6,974 | +8.3% | Form 10-K (filed 2019-02-20) ↗ |
| Q3 2017 | Oct 1, 2017 | 6,599 | +7.1% | Form 10-K (filed 2019-02-20) ↗ |
| Q2 2017 | Jul 2, 2017 | 6,726 | +4.9% | Form 10-K (filed 2019-02-20) ↗ |
| Q1 2017 | Apr 2, 2017 | 6,293 | +3.0% | Form 10-K (filed 2019-02-20) ↗ |
| Q4 2016 | Jan 1, 2017 | 6,442 | – | Form 10-K (filed 2018-02-21) ↗ |
| Q3 2016 | Oct 2, 2016 | 6,159 | – | Form 10-K (filed 2018-02-21) ↗ |
| Q2 2016 | Jul 3, 2016 | 6,409 | – | Form 10-K (filed 2018-02-21) ↗ |
| Q1 2016 | Apr 3, 2016 | 6,109 | – | Form 10-K (filed 2018-02-21) ↗ |
Breakdown
What makes up medtech segment total — worldwide sales ($m)
- MedTech Segment Total — U.S. sales ($M)4,512 · Q3 2026
- MedTech Segment Total — International sales ($M)4,130 · Q3 2026
- MedTech Segment Total — Worldwide reported growth YoY (%)2.5% · Q3 2026
- MedTech Segment Total — Worldwide operational (constant-currency) growth YoY (%)2.5% · Q3 2026
- MedTech — Worldwide adjusted operational growth ex-A&D YoY (%)2.5% · Q3 2026
- Cardiovascular (formerly Interventional Solutions) Franchise — Worldwide sales ($M)2,307 · Q3 2026
- Surgery Franchise — Worldwide sales ($M)2,528 · Q3 2026
- Orthopaedics Franchise — Worldwide sales ($M)2,345 · Q3 2026
- Vision Franchise — Worldwide sales ($M)1,461 · Q3 2026
- Diabetes Care Franchise [divested FY2018–FY2019] — Worldwide sales ($M)0 · Q4 2019
- Diagnostics Franchise [divested through FY2018] — Worldwide sales ($M)0 · Q4 2018
Cite this data
StockData. (2026). Johnson & Johnson MedTech Segment Total — Worldwide sales ($M) ($M), quarterly Q1 2016–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/seg_medtech
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.